Literature DB >> 9744250

Measurement and determinants of tuberculosis outcome in Karonga District, Malawi.

J R Glynn1, D K Warndorff, P E Fine, M M Munthali, W Sichone, J M Pönnighaus.   

Abstract

Evaluation of disease outcome is central to the assessment of tuberculosis (TB) control programmes. In the study reported in this article we examined the factors influencing the measurement of outcome, survival rates during and after treatment, smear conversion rates, and relapse rates for patients diagnosed with TB in a rural area of Malawi between 1986 and mid-1994. Patients with less certain diagnoses of TB were more likely to die than those with confirmed TB, both among those who were seropositive and those who were seronegative to human immunodeficiency virus (HIV). The mortality rate among smear-positive patients with a separate culture-positive specimen was half that of patients with no such diagnostic confirmation. Patients not registered by the Ministry of Health had much higher mortality and default rates than did registered patients. Among smear-positive patients, HIV serostatus was the most important influence on mortality both during and after treatment (crude hazard ratios (95% confidence intervals) = 5.6 (3.0-10) and 7.7 (3.4-17), resp.), but HIV serostatus did not influence smear conversion rates. The initial degree of smear positivity influenced smear conversion rates, but not mortality rates. No significant predictors of relapse were identified. Unless considerable care is taken to include all TB patients, and to exclude nontuberculous patients, recorded TB outcome statistics are difficult to interpret and may be misleading. In populations with high rates of HIV infection, TB target cure rates of 85% are unrealistic. When new interventions are assessed it cannot be assumed that factors which influence the smear conversion rate will also influence the mortality rate.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Africa; Africa South Of The Sahara; Death Rate; Demographic Factors; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Hiv Infections; Infections; Malawi; Measurement; Mortality; Organization And Administration; Population; Population Dynamics; Program Evaluation; Programs; Research Methodology; Research Report; Sampling Studies; Studies; Surveys; Treatment; Tuberculosis; Viral Diseases

Mesh:

Year:  1998        PMID: 9744250      PMCID: PMC2305706     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  14 in total

1.  Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group.

Authors: 
Journal:  Lancet       Date:  1996-07-06       Impact factor: 79.321

2.  Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries.

Authors:  C J Murray; E DeJonghe; H J Chum; D S Nyangulu; A Salomao; K Styblo
Journal:  Lancet       Date:  1991-11-23       Impact factor: 79.321

3.  The global tuberculosis situation and the new control strategy of the World Health Organization.

Authors:  A Kochi
Journal:  Tubercle       Date:  1991-03

4.  The point of view of a high prevalence country: Malawi.

Authors:  D S Nyangulu
Journal:  Bull Int Union Tuberc Lung Dis       Date:  1991-12

5.  The distribution and implications of BCG scars in northern Malawi.

Authors:  P E Fine; J M Ponnighaus; N Maine
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

6.  Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya.

Authors:  M Hawken; P Nunn; S Gathua; R Brindle; P Godfrey-Faussett; W Githui; J Odhiambo; B Batchelor; C Gilks; J Morris
Journal:  Lancet       Date:  1993-08-07       Impact factor: 79.321

7.  Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire.

Authors:  J H Perriëns; R L Colebunders; C Karahunga; J C Willame; J Jeugmans; M Kaboto; Y Mukadi; P Pauwels; R W Ryder; J Prignot
Journal:  Am Rev Respir Dis       Date:  1991-10

8.  Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire.

Authors:  A N Ackah; D Coulibaly; H Digbeu; K Diallo; K M Vetter; I M Coulibaly; A E Greenberg; K M De Cock
Journal:  Lancet       Date:  1995-03-11       Impact factor: 79.321

9.  The Karonga Prevention Trial: a leprosy and tuberculosis vaccine trial in northern Malaŵi. I. Methods of the vaccination phase.

Authors:  J M Pönnighaus; P E Fine; L Bliss; P J Gruer; B Kapira-Mwamondwe; E Msosa; R J Rees; D Clayton; M C Pike; J A Sterne
Journal:  Lepr Rev       Date:  1993-12       Impact factor: 0.537

10.  The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia.

Authors:  A M Elliott; B Halwiindi; R J Hayes; N Luo; A G Mwinga; G Tembo; L Machiels; G Steenbergen; J O Pobee; P P Nunn
Journal:  J Trop Med Hyg       Date:  1995-02
View more
  19 in total

1.  What has Karonga taught us? Tuberculosis studied over three decades.

Authors:  A C Crampin; J R Glynn; P E M Fine
Journal:  Int J Tuberc Lung Dis       Date:  2009-02       Impact factor: 2.373

Review 2.  A systematic review of published literature describing factors associated with tuberculosis recurrence in people living with HIV in Africa.

Authors:  Yoshan Moodley; Kumeren Govender
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

3.  Drivers of inequality in Millennium Development Goal progress: a statistical analysis.

Authors:  David Stuckler; Sanjay Basu; Martin McKee
Journal:  PLoS Med       Date:  2010-03-02       Impact factor: 11.069

4.  What happens to ART-eligible patients who do not start ART? Dropout between screening and ART initiation: a cohort study in Karonga, Malawi.

Authors:  Nuala McGrath; Judith R Glynn; Jacqueline Saul; Katharina Kranzer; Andreas Jahn; Frank Mwaungulu; Msenga H C Ngwira; Hazzie Mvula; Fipson Munthali; Venance Mwinuka; Lorren Mwaungulu; Paul E M Fine; Amelia C Crampin
Journal:  BMC Public Health       Date:  2010-10-12       Impact factor: 3.295

5.  Smear microscopy and culture conversion rates among smear positive pulmonary tuberculosis patients by HIV status in Dar es Salaam, Tanzania.

Authors:  Mbazi Senkoro; Sayoki G Mfinanga; Odd Mørkve
Journal:  BMC Infect Dis       Date:  2010-07-16       Impact factor: 3.090

6.  Evaluation and determinants of outcome of tuberculosis treatment.

Authors:  D Maher; P Nunn
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

Review 7.  Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis.

Authors:  Peter MacPherson; Rein M G J Houben; Judith R Glynn; Elizabeth L Corbett; Katharina Kranzer
Journal:  Bull World Health Organ       Date:  2013-11-22       Impact factor: 9.408

8.  Sputum completion and conversion rates after intensive phase of tuberculosis treatment: an assessment of the Rwandan control program.

Authors:  Felix R Kayigamba; Mirjam I Bakker; Veronicah Mugisha; Michel Gasana; Maarten F Schim van der Loeff
Journal:  BMC Res Notes       Date:  2012-07-16

9.  Factors associated with mortality in HIV-infected and uninfected patients with pulmonary tuberculosis.

Authors:  Ferdinand M Mugusi; Saurabh Mehta; Eduardo Villamor; Willy Urassa; Elmar Saathoff; Ronald J Bosch; Wafaie W Fawzi
Journal:  BMC Public Health       Date:  2009-11-12       Impact factor: 3.295

10.  The effect of empirical and laboratory-confirmed tuberculosis on treatment outcomes.

Authors:  Osman Abdullahi; Ngari Moses; Deche Sanga; Willetts Annie
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.